4basebio

1. 28 Sep 26
   Half-year Results

   Cambridge, UK, 28 September 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing for next-generation genomic medicines and advanced therapies, announces its unaudited half-year results for the six months ended 30 June 2026 (“H1 2026”).

   RNS 9792945 ↗
2. 28 Sep 26
   4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company's Phase I Cell Therapy Program

   4basebio and TriLink BioTechnologies Partner to Advance Leading Pharmaceutical Company’s Phase I Cell Therapy Program

   RNS 9792928 ↗
3. 07 Sep 26
   4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine

   4basebio Expands DNA Offering to Meet Growing Demand for Personalised Medicine

   RNS 9757825 ↗
4. 26 Aug 26
   4basebio and Genezen Enter into Strategic Collaboration to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing

   Commercial collaboration combines 4basebio’s synthetic DNA technology with Genezen’s viral vector development and manufacturing expertise to support gene therapy programs from early development through clinical and commercial manufacturing.

   RNS 9740689 ↗
5. 26 Aug 26
   4basebio Enters into Strategic Collaboration and Marketing Agreement with Genezen to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing

   4basebio Enters into Strategic Collaboration and Marketing Agreement with Genezen to Advance Synthetic, Cell-Free DNA Platforms for Next-Generation Viral Vector Manufacturing

   RNS 9740155 ↗
6. 08 Jul 26
   Director Appointment

   4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, is pleased to announce the apppointent of Mr.

   RNS 9657446 ↗
7. 16 Jun 26
   Notice of Investor Presentation

   – 4basebio PLC (AIM: 4BB),a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that it will provide a live investor presentation on 29 June 2026.

   RNS 9619754 ↗
8. 15 Jun 26
   4basebio Appoints Dr. Jeff Coller to Strategic Advisory Board

   , brings deep expertise to accelerate synthetic DNA and mRNA manufacturing

   RNS 9617349 ↗
9. 22 May 26
   Director/PDMR Shareholding Director buys

   4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that on 21 May 2026 it was informed that Dr.

   RNS 9582362 ↗
10. 20 May 26
    Final Results and Notice of AGM

    a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces its audited final results for the year ended 31 December 2025.

    RNS 9576804 ↗
11. 20 May 26
    4basebio Signs Clinical Supply Agreement to Support Phase II Clinical Trial

    Oncology focused biotech to utilise 4basebio’s opDNA® technology to support Phase II clinical trial of immunotherapy candidate

    RNS 9576789 ↗
12. 14 May 26
    Appointment of Chief Financial Officer and Board Changes New CFO

    Appointment of Chief Financial Officer and Board Changes

    RNS 9567722 ↗
13. 11 May 26
    4basebio Launches Enzymatic ssDNA Platform

    Overcomes critical manufacturing and performance bottlenecks associated with traditional chemical synthesis, providing faster and more reliable ssDNA manufacturing to aid commercial scale up

    RNS 9560687 ↗
14. 31 Mar 26
    Lease of Manufacturing Facility

    4basebio announces major expansion to support the growing demand of RUO and HQ synthetic DNA with lease of an innovation hub and manufacturing facility in Cambridge, UK

    RNS 9499490 ↗
15. 12 Mar 26
    Appointment of COO New CEO

    strengthens operations, appointing Scott Lorimer as Chief Operating Officer

    RNS 9470575 ↗
16. 03 Mar 26
    Appointment of CCO

    strengthens commercial leadership, promoting Christine Wolosin to Chief Commercial Officer

    RNS 9454951 ↗
17. 16 Feb 26
    Director/PDMR Shareholding Director buys

    – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that on 13 February 2026 it...

    RNS 9431591 ↗
18. 11 Feb 26
    Director/PDMR Shareholding Director buys

    (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products, announces that on 10 February 2026 it was informed...

    RNS 9426514 ↗
19. 10 Feb 26
    Leadership Changes New CEO

    – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant GMP-grade synthetic DNA products

    RNS 9422753 ↗
20. 27 Oct 25
    Synthetic opDNA® utilised in Phase I/II US clinical trials

    Synthetic opDNA® utilised in Phase I/II US clinical trials

    RNS 9195300 ↗
21. 10 Oct 25
    Result of General Meeting

    Cambridge, UK, 10 October 2025 - 4basebio PLC (AIM: 4BB), an innovation-led provider of novel synthetic DNA products and a non-viral, thermostable nucleic acid delivery platform announces that all of the resolutions proposed at its Extraordinary General...

    RNS 9163785 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.